# A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

> **NCT02032277** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 634 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Placebo
- **DRUG:** Doxorubicin
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Veliparib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02032277
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-02
- **Primary completion:** 2016-03-18
- **Final completion:** 2020-11-12
- **Target enrollment:** 634 (ACTUAL)
- **Last updated:** 2021-01-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02032277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02032277, "A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02032277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*